Invasive Breast Carcinoma
Mass-Forming Ductal Carcinoma In Situ >10 mm on Ultrasonography: Sonographic-Pathological Correlation Underlying Mass Formation and Implications for Invasion Assessment.
Michishita Y, et al
A retrospective study of 52 surgically confirmed breast DCIS cases presenting as masses larger than 10 mm on ultrasound identified three distinct sonographic-pathological patterns — intracystic (9/52, 17.3%), clustered outline (34/52, 65.4%), and sclerosing stromal (7/52, 13.5%) — and found that bac…
Source →Measuring Radiologist Workload After AI Triage in Breast Cancer Screening.
Sorin V, et al
A new session-level reporting standard is proposed to more accurately quantify radiologist workload following AI triage in breast cancer screening, replacing simple reading counts with total active human interpretation minutes per 1,000 women screened. The authors argue that reading count alone fail…
Source →Interval Invasive Cancers in Population Screening: A Meta-analysis of Digital Breast Tomosynthesis vs. Digital Mammography.
Ferre R, et al
A meta-analysis of 13 comparative studies encompassing more than 1.4 million screening examinations — 548,368 with digital breast tomosynthesis (DBT) and 859,256 with standard digital mammography (DM), yielding 4,370 invasive interval breast cancers — found that DBT does not meaningfully reduce the …
Source →Baseline multiparametric MRI combined with clinical factors for predicting pathological complete response of breast cancer after Neoadjuvant chemotherapy.
Guo K, et al
A new multiparametric MRI model combining diffusion-derived shear modulus (μdiff) and diffusion coefficient (D) with estrogen receptor (ER) status can predict whether breast cancer will completely disappear after neoadjuvant chemotherapy with remarkable accuracy — achieving an AUC of 0.921, 91.4% se…
Source →[Datopotamab-deruxtecan in previously treated RH+/HER2- advanced or metastatic breast cancer].
Roberts A, et al
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, demonstrated clinically meaningful benefit in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had received prior therapy, as reviewed in this article published in Bulletin du …
Source →Clinicopathological, molecular genetics features and treatment progress of breast squamous cell carcinoma
Ding JN, et al
This review article examines the clinicopathological and molecular genetic characteristics of breast squamous cell carcinoma (BSqCC), a rare and aggressive subtype of metaplastic breast carcinoma, alongside advances in its treatment. BSqCC is notable for its triple-negative receptor profile, high ra…
Source →Preoperative Resting-State EEG Features Associated With Chronic Postoperative Pain After Breast Cancer Surgery: A Prospective Cohort Study.
Li Y, et al
A prospective cohort study of 84 female breast cancer patients found that preoperative resting-state EEG gamma-band power at frontal electrode sites (F3, Fz, F4) and stronger gamma-band functional connectivity involving frontal, insular, and cingulate regions were associated with clinically signific…
Source →Delays in Breast Cancer Surgical Care Following Oncology Surgeon Departures.
Cornelius SL, et al
Each additional breast cancer surgeon departure from a hospital service area was associated with a 4% increase in the odds of surgical delay exceeding 60 days (95% CI: 1.02–1.05; P<0.001), according to a Medicare claims-based study of 122,159 breast cancer patients diagnosed between 2017 and 2019. N…
Source →Assessment of bone health-related quality of life in postmenopausal women with non-metastatic breast cancer receiving cytotoxic chemotherapy: A prospective cohort study.
Nisha Y, et al
A prospective cohort study of 109 postmenopausal women with non-metastatic breast cancer found that anthracycline and taxane-based chemotherapy caused significant worsening of bone health-related quality of life across all measured domains, with total QUALEFFO-31 scores rising from 19.98 ± 8.34 at b…
Source →Primary Mammary Angiosarcoma in a Postmenopausal Woman: A Case Report.
Liu T, et al
A 51-year-old postmenopausal woman with a rapidly enlarging left breast mass was diagnosed with stage I (T1N0M0) primary breast angiosarcoma and achieved no recurrence or metastasis over more than 5 years of follow-up after radical two-stage surgical resection followed by sequential adjuvant chemoth…
Source →Large-scale pleiotropic analysis across cancers reveals shared genetic mechanisms and identifies novel functional genes.
Wu X, et al
A large-scale pleiotropic analysis of genome-wide association study summary statistics from 37 cancer types (N = 433,836) identified 75,243 significant pleiotropic SNPs across 372 cancer pairs, 2,527 pleiotropic risk loci, and 4,272 candidate pleiotropic genes, revealing extensive shared genetic arc…
Source →Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study
Dixon-Douglas JR, et al
This independent external validation (the CATALINA study) tested whether artificial intelligence algorithms that quantify tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer hold up on data they were not trained on. The material was pooled from seven randomised clinical trials wi…
Source →Prediction of Ki-67 Status in Breast Cancer Using a Habitat-Guided 2.5D Multiparametric MRI Deep Learning Model.
Miao Z, et al
A habitat-guided 2.5D deep learning model based on multiparametric MRI achieved an area under the curve (AUC) of 0.821 and a sensitivity of 0.804 in predicting Ki-67 proliferation status in breast cancer across an independent cross-vendor test set of 100 patients, significantly outperforming both a …
Source →Ultrafast breast MRI to differentiate between molecular subtypes of breast cancer: a systematic review and meta-analysis.
Terhaar H, et al
A systematic review and meta-analysis of nine studies encompassing 1,371 breast lesions found that ultrafast dynamic contrast-enhanced MRI (UF-MRI) can differentiate breast cancer molecular subtypes with subtype-specific accuracy: Luminal tumors achieved the highest pooled sensitivity of 0.90, speci…
Source →TRIB3 promotes triple-negative breast cancer metastasis by restricting lipophagy through the PI3K/AKT/mTOR signaling pathway.
Ruan L, et al
A new study published in Cellular Signalling reveals that the protein TRIB3 drives metastasis in triple-negative breast cancer (TNBC) by blocking a cellular fat-recycling process called lipophagy, making it a promising new therapeutic target. Using public gene-expression databases, patient tissue sa…
Source →